JM McIntosh

First name:
JM
Last name:
McIntosh
Wooters, T. E., Smith, A. M., Pivavarchyk, M., Siripurapu, K. B., McIntosh, J. M., Zhang, Z., et al. (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal Of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x
View
Smith, A. M., Pivavarchyk, M., Wooters, T. E., Zhang, Z., Zheng, G., McIntosh, J. M., et al. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)
View
Dwoskin, L. P., Wooters, T. E., Sumithran, S. P., Siripurapu, K. B., Joyce, B. M., Lockman, P. R., et al. (2008). N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal Of Pharmacology And Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630
View
Beckmann, J. S., Meyer, A. C., Pivavarchyk, M., Horton, D. B., Zheng, G., Smith, A. M., et al. (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4
View